Financial Performance - For the three months ended June 30, 2025, the company reported a net loss of $5.1 million, compared to a net loss of $1.4 million for the same period in 2024, representing a significant increase in losses [78]. - The company incurred a total net loss of $7.2 million for the six months ended June 30, 2025, compared to a net loss of $7.7 million for the same period in 2024 [78]. - The company reported negative cash flow from operations of approximately $1.6 million for the six months ended June 30, 2025, compared to $3.5 million for the same period in 2024 [101]. Expenses - Research and development expenses for the three months ended June 30, 2025, were $0.04 million, a decrease from $0.6 million in the same period of 2024, primarily due to a credit received in 2024 [89]. - General and administrative expenses increased to $5.0 million for the three months ended June 30, 2025, from $0.9 million in 2024, largely due to a $4.6 million increase in stock compensation expenses [94]. - The company expects research and development expenses to increase as it advances Telomir-1 into clinical trials and pursues regulatory approvals [93]. Cash Position - As of June 30, 2025, the company had cash and cash equivalents of approximately $0.8 million and an accumulated deficit of approximately $37.8 million [101]. - The company has entered into an unsecured Promissory Note with the Starwood Trust, allowing it to borrow up to $5 million, with no amounts borrowed as of June 30, 2025 [99]. Funding - The company raised $3 million in equity financing through a direct investment by The Bayshore Trust, issuing 333,333 restricted shares at $3.00 per share, an 18% premium to the closing share price on the execution date [100]. Revenue Generation - The company has not generated any revenue since inception and does not anticipate doing so until successful completion of preclinical and clinical development [91].

Part I. Financial Information This section covers the company's unaudited condensed financial statements and management's discussion and analysis [Item 1. Condensed Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Financial%20Statements%20(unaudited)) Unaudited condensed financial statements for Telomir Pharmaceuticals, Inc. are presented for Q1 2025 and year-end 2024 - The company is classified as a non-accelerated filer and a smaller reporting company[4](index=4&type=chunk) - As of May 14, 2025, there were **29,762,671** shares of registrant common stock issued and outstanding[5](index=5&type=chunk) [Condensed Balance Sheets](index=4&type=section&id=Condensed%20Balance%20Sheets) This section presents the company's financial position as of March 31, 2025, and December 31, 2024 Condensed Balance Sheets (Unaudited) | Metric | March 31, 2025 | December 31, 2024 | | :-------------------------------- | :------------- | :---------------- | | Cash and cash equivalents | $402,999 | $1,266,131 | | Total current assets | $491,188 | $1,324,005 | | Total assets | $491,188 | $1,324,005 | | Total current liabilities | $652,294 | $680,968 | | Total liabilities | $652,294 | $680,968 | | Total stockholders' equity (deficit) | $(161,106) | $643,037 | [Condensed Statements of Operations](index=5&type=section&id=Condensed%20Statements%20of%20Operations) This section presents the company's financial performance, including revenues and net loss, for Q1 2025 and Q1 2024 Condensed Statements of Operations (Unaudited) | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Revenues | $0 | $0 | | General and administrative expenses | $1,850,786 | $741,541 | | Related party travel costs | $0 | $370,500 | | Research and development expenses | $336,996 | $804,023 | | Total operating costs | $2,187,782 | $1,916,064 | | Interest income (expense), net | $7,954 | $(4,338,543) | | Net loss | $(2,179,828) | $(6,254,607) | | Basic and diluted loss per share | $(0.07) | $(0.23) | | Weighted average common stock shares outstanding | 29,762,671 | 29,276,481 | [Condensed Statements of Changes in Stockholders' Equity (Deficit)](index=6&type=section&id=Condensed%20Statements%20of%20Changes%20in%20Stockholders'%20Equity%20(Deficit)) This section outlines changes in the company's stockholders' equity (deficit) for Q1 2025 and Q1 2024 Condensed Statements of Changes in Stockholders' Equity (Deficit) - Three Months Ended March 31, 2025 (Unaudited) | Item | Three Months Ended March 31, 2025 | | :-------------------------- | :-------------------------------- | | Balances, December 31, 2024 | $643,037 | | Stock based compensation | $1,375,686 | | Net loss | $(2,179,828) | | Balances, March 31, 2025 | $(161,106) | Condensed Statements of Changes in Stockholders' Equity (Deficit) - Three Months Ended March 31, 2024 (Unaudited) | Item | Three Months Ended March 31, 2024 | | :-------------------------------- | :-------------------------------- | | Balances, December 31, 2023 | $3,438,204 | | Issuance of common stock for cash, net | $5,832,973 | | Net loss | $(6,254,607) | | Balances, March 31, 2024 | $3,016,570 | [Condensed Statements of Cash Flows](index=7&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) This section presents the company's cash flows from operating and financing activities for Q1 2025 and Q1 2024 Condensed Statements of Cash Flows (Unaudited) | Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------- | :-------------------------------- | :-------------------------------- | | Net cash from operating activities | $(863,132) | $(1,939,415) | | Net cash from financing activities | $0 | $5,212,498 | | Net change in cash and cash equivalents | $(863,132) | $3,273,083 | | Cash and cash equivalents, end of period | $402,999 | $3,274,314 | [Notes to Condensed Financial Statements (unaudited)](index=8&type=section&id=Notes%20to%20Condensed%20Financial%20Statements%20(unaudited)) This section provides explanatory notes to the unaudited condensed financial statements - The accompanying unaudited condensed financial statements are prepared in accordance with GAAP for interim financial information and Regulation S-X[17](index=17&type=chunk) [Note 1. Description of business and summary of significant accounting policies](index=8&type=section&id=Note%201.%20Description%20of%20business%20and%20summary%20of%20significant%20accounting%20policies) This note describes the company's business, Telomir-1, and significant accounting policies - Telomir-1 is a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression[16](index=16&type=chunk) - Telomir-1 may help protect against age-related conditions (Progeria, Wilson's disease, Age-related Macular Degeneration, Type 2 Diabetes, cancer, Alzheimer's disease) and mitigate viral infection severity[16](index=16&type=chunk) - Research and development costs are expensed in the period in which they are incurred[18](index=18&type=chunk) - As of March 31, 2025, the Company had approximately **$0.2 million** in cash in excess of FDIC limits[21](index=21&type=chunk) - The Company does not expect the adoption of new accounting guidance (ASU 2024-03 and ASU 2023-09) to have a material impact on its consolidated financial statements[29](index=29&type=chunk)[31](index=31&type=chunk) [Note 2. Going concern](index=11&type=section&id=Note%202.%20Going%20concern) This note discusses the company's financial condition and its ability to continue as a going concern - As of March 31, 2025, the Company had cash of approximately **$0.4 million**, used approximately **$0.9 million** in operations, and reported a net loss of **$2.2 million** for the three months ended March 31, 2025[34](index=34&type=chunk) - The Company had a stockholders' deficit and working capital deficit of approximately **$0.2 million** as of March 31, 2025, compared to stockholders' equity of approximately **$0.6 million** at December 31, 2024[34](index=34&type=chunk) - These factors raise substantial doubt about the Company's ability to continue as a going concern for at least the next 12 months, necessitating significant additional external funding[35](index=35&type=chunk)[36](index=36&type=chunk) [Note 3. License agreement, related party](index=11&type=section&id=Note%203.%20License%20agreement,%20related%20party) This note details the company's exclusive license agreement for Telomir-1 with related party MIRALOGX, LLC - The Company licenses U.S. patent rights for Telomir-1 from MIRALOGX, LLC, an entity established by the Company's founder and sole inventor of Telomir-1[37](index=37&type=chunk) - The exclusive perpetual license covers human and animal therapeutic uses, with an **8% royalty** on net sales and non-royalty bearing milestone revenue, though no payments have been made to date[39](index=39&type=chunk)[40](index=40&type=chunk) - The patent rights are expected to extend through 2043, with potential for additional patent terms[41](index=41&type=chunk) [Note 4. Related party transactions](index=12&type=section&id=Note%204.%20Related%20party%20transactions) This note describes various transactions and agreements between the company and related parties - An amount of **$0.1 million** in working capital advances from companies under common control remains outstanding as of March 31, 2025[43](index=43&type=chunk) - The Company has an unsecured Promissory Note and Loan Agreement with the Starwood Trust (a related party) for up to **$5 million** at **7% interest**, due on September 24, 2026; no amounts have been borrowed as of March 31, 2025[44](index=44&type=chunk) - On December 9, 2024, Starwood Trust purchased **142,857 shares** of unregistered common stock for **$1.0 million**[46](index=46&type=chunk) [Note 5. Stockholders' equity (deficit)](index

Drug Development and Mechanism - Telomir-1 is a novel oral small molecule designed to combat oxidative stress and may protect against age-related conditions, including Progeria and Type 2 Diabetes[16]. - Preclinical studies indicate that Telomir-1 can normalize fasting plasma glucose levels and improve insulin sensitivity, with significant reductions in HOMA-IR values observed[35][38]. - The drug demonstrated a statistically significant increase in lifespan and health span in aged nematode populations, suggesting potential for longevity treatments[42][43]. - Telomir-1 fully reversed oxidative stress by normalizing Reactive Oxygen Species (ROS) levels and provided strong protection against copper-induced toxicity[50]. - Telomir-1's mechanism of action targets iron metabolism, addressing oxidative stress and insulin resistance, differentiating it from current diabetes treatments[37]. - The company is actively investigating Telomir-1's potential in treating Wilson's disease, a rare genetic disorder affecting approximately 1 in 30,000 individuals[32]. - Ongoing studies are evaluating Telomir-1's effects on copper toxicity and its therapeutic potential in various age-related diseases and viral infections[48]. - Telomir-1 has shown promise in reversing biological aging markers in preclinical studies, indicating its potential as a groundbreaking therapy for age-related conditions[44]. Market Potential - Telomir-1 is projected to address chronic diseases that account for over 75% of healthcare spending in the U.S., exceeding $4 trillion annually[54]. - The anti-aging drug market was valued at approximately $91.05 billion in 2024 and is expected to reach $160.24 billion by 2031, growing at a CAGR of 7.32%[54]. - The Type 2 Diabetes market in the U.S. was valued at approximately $30.47 billion in 2022, driven by rising prevalence and demand for advanced therapies[63]. - The global Age-related Macular Degeneration market is projected to reach $18 billion by 2030, growing at a CAGR of 8.2% from 2024 to 2030[63]. - The U.S. oncology market was valued at $74.1 billion in 2023 and is projected to reach $180.12 billion by 2033, growing at a CAGR of 9.2% from 2024 to 2033[64]. - The global antiviral drugs market was valued at approximately $49.8 billion in 2022 and is projected to reach around $71.1 billion by 2032, reflecting a CAGR of 3.73%[67]. - The treatment market for avian influenza (bird flu) was estimated at $22.06 billion in 2023 and is expected to grow at a CAGR of 8.18%, reaching approximately $38.27 billion by 2030[68]. Regulatory and Clinical Development - The company aims to submit Investigational New Drug (IND) and Investigational New Animal Drug (INAD) applications to the FDA to progress to clinical trials[25]. - The company plans to submit an IND application for Telomir-1 in Q4 2025, with first-in-human trials anticipated in early 2026[52][59]. - Safety studies for Telomir-1 are scheduled for Q2 2025, with the aim of advancing its clinical development[52]. - The regulatory approval processes with the FDA are lengthy and inherently unpredictable[113]. - Clinical trials for the company's product candidates are expensive, time-consuming, and susceptible to change, delay, or termination[111]. - The company is dependent on the successful pre-clinical and clinical development, FDA regulatory approval, and commercialization of its product candidates, principally Telomir-1[145]. - The company must comply with extensive regulations, including FDA's Good Laboratory Practice and Good Clinical Practice, to avoid sanctions[176]. - Regulatory authorities may interrupt or halt clinical trials if serious adverse events or safety risks are identified, potentially delaying product approval[188]. Financial Challenges - The company is in the early development stage with no revenues, raising substantial doubt about its ability to continue as a going concern[100]. - The company has an accumulated deficit of $30.6 million as of December 31, 2024, and $14.1 million as of December 31, 2023, indicating significant financial challenges ahead[128]. - The company has generated no revenue to date and is entirely dependent on external financing to continue operations[131]. - The company anticipates needing additional funding to fully implement its business plan and achieve growth, with expectations of adequate resources available by the first quarter of 2026[132]. - The company will need to raise additional financing to continue its operations[102]. - The company has not achieved profitability and does not expect to do so in the near future[103]. - For the year ended December 31, 2024, the company reported a net operating cash outflow of $5.1 million and a net cash inflow from financing activities of $6.3 million, compared to a net operating cash outflow of $3.9 million and a net cash inflow from financing activities of $3.9 million for the year ended December 31, 2023[156]. Competition and Market Risks - The company expects to face intense competition from firms with greater resources and experience[109]. - Established companies may have a competitive advantage due to their size, financial resources, and institutional networks, impacting the company's ability to develop and commercialize its drug candidates[154]. - The commercial success of product candidates will depend on various factors, including the willingness of physicians to prescribe products and payers' willingness to reimburse[149]. - The company faces intense competition from multinational pharmaceutical companies and specialized biotechnology companies, which may have greater resources and experience[153]. Intellectual Property and Legal Risks - The company has significant uncertainties regarding its intellectual property rights, as it does not own the rights to Telomir-1 and relies on a license from MIRALOGX[117]. - The company recognizes the high rate of failure for drug candidates in clinical trials, which poses a risk to its product development[114]. - The company may face litigation related to intellectual property rights, which could divert resources and negatively impact its operations[126]. - The company is required to pay an 8% royalty on net sales or revenue in exchange for the exclusive license to Telomir-1, which could impact profitability[124]. - The company faces risks related to reliance on third parties for clinical trials, which may adversely affect its ability to develop and commercialize product candidates[115]. Operational and Management Challenges - The company has a limited operating history, making it difficult to accurately evaluate its operations[101]. - The inability to hire or retain experienced management personnel could adversely affect the company's ability to execute its business plan and harm operating results[163]. - The company utilizes part-time employees and contractors to support its organizational needs[88]. - The company is continuously enhancing its IT systems to support planned growth, which includes potential delays and substantial capital expenditures[166]. - Security breaches and data loss could compromise sensitive information, leading to legal claims and regulatory penalties, adversely affecting the company's reputation and operations[168]. Supply Chain and Manufacturing Risks - The company relies on third parties for clinical trials and manufacturing, increasing the risk of delays or failures in obtaining marketing approval for its product candidates[190]. - There is a risk that third-party manufacturers may not comply with cGMP requirements, which could lead to sanctions and affect the supply of products[195]. - The company does not have long-term supply agreements with third-party manufacturers, increasing the risk of not obtaining sufficient quantities of products in a timely manner[196]. - The company relies on a limited number of suppliers for critical materials and components, which poses risks of delays and operational disruptions[204]. Shareholder and Governance Issues - Approximately 23,891,902 shares of common stock are subject to lock-up agreements and will become eligible for public sale by February 9, 2025, potentially impacting stock price[206]. - Founding stockholders and existing officers control over 70% of the company's common stock, which may influence shareholder votes and corporate decisions[208]. - Compliance with public company regulations will increase legal and financial costs, potentially diverting management's focus from revenue-generating activities[211]. - The company may face challenges in attracting and retaining qualified board members and executive officers due to increased costs of liability insurance[214]. - Future collaboration arrangements may not be successful, affecting the company's ability to develop and commercialize product candidates[201].

Core Insights - Telomir Pharmaceuticals, Inc. has revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing key parameters of Type 2 diabetes mellitus, including significant reductions in fasting plasma glucose levels and improved oral glucose homeostasis [1][2] - The study also indicated that Telomir-1 improves insulin resistance to near pre-diabetic levels and enhances survival rates in treated subjects [3] - Telomir-1 addresses oxidative stress and beta-cell damage by normalizing iron metabolism [3] Research Advancements - Telomir Pharmaceuticals is advancing research on Telomir-1's effects on various conditions, including: - Progeria: Evaluating effects on human progeria cell lines and nematode models [5] - Diabetic Mouse Models: Validating efficacy in Type 2 diabetes [5] - Alzheimer's Disease: Initiating studies on cognitive decline and neurodegeneration [5] - Osteoarthritis and Inflammatory Diseases: Assessing its role in managing joint health [5] - Cancer Models: Exploring applications in age-related oncological conditions [5] Market Reaction - Following the announcement, TELO stock increased by 15.4%, reaching $4.905 [6]

Financial Performance - For the nine months ended September 30, 2024, the company incurred net losses of $13.6 million, compared to $3.7 million for the same period in 2023, representing a significant increase in losses [53][68]. - The company has an accumulated deficit of approximately $27.7 million as of September 30, 2024 [72]. - The company expects to incur additional losses until significant revenue is generated, which is not anticipated in the near future [72]. Expenses - Research and development expenses for the nine months ended September 30, 2024, were $1.9 million, up from $1.4 million in the same period of 2023, primarily related to toxicology studies and pre-clinical research [58]. - General and administrative expenses surged to $7.0 million for the nine months ended September 30, 2024, compared to $0.2 million in the prior year, largely due to increased payroll costs and stock options granted [59]. - Related party travel costs decreased significantly from $1.3 million in the nine months ended September 30, 2023, to $0.4 million in the same period of 2024 [60]. Cash Flow and Financing - The company had cash of approximately $0.8 million as of September 30, 2024, and used approximately $4.5 million in operations during the nine months ended September 30, 2024 [67][72]. - Financing activities provided $5.3 million of cash for the nine months ended September 30, 2024, primarily from proceeds of $5.8 million from the sale of Common Stock [79]. - The company anticipates that its current cash and cash equivalents will not be sufficient to fund operations through the third quarter of 2025 without additional financing [74]. - The company entered into a Promissory Note and Loan Agreement with the Starwood Trust, allowing borrowing of up to $5 million, subject to certain conditions [71]. Regulatory and Reporting - The company is classified as a smaller reporting company and is not required to provide market risk disclosures as per Rule 12b-2 of the Exchange Act [81].

Core Insights - Telo Genomics Corp. is advancing its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma patients as part of the TELO-DMRD clinical validation study [1][2] Group 1: Company Overview - Telo Genomics Corp. is a biotech company focused on developing a leading telomere technology platform with applications in oncology, particularly in measuring genomic instability [1][7] - The company is pioneering liquid biopsy technologies, which are less invasive and more easily replicated than traditional diagnostic methods [7] Group 2: Clinical Trials and Studies - The TELO-DMRD clinical trial, conducted in collaboration with McGill University, aims to evaluate the sensitivity of Telo's MRD assays using Adaptive Biotechnologies' clonoSEQ assay technology [2][4] - The study plans to include up to ten patients, with the potential for expansion based on initial results, and the first patient samples have already been analyzed [3][4] Group 3: Objectives and Applications - The clinical trials have two main objectives: to identify and quantify MRD cells in patients' blood post-marrow transplantation and to profile these cells to assess disease aggressiveness using Telo's proprietary technology [4] - The MRD tests are designed to be liquid biopsy-based, aligning with the trend towards precision medicine in oncology [4] Group 4: Market Potential - The global MRD testing market is projected to reach USD 4.1 billion by 2032, indicating substantial growth potential in the industry [6]

Financial Performance - For the six months ended June 30, 2024, the company incurred net losses of $7.6 million, compared to $2.0 million for the same period in 2023, representing a 280% increase in losses [45]. - The company expects to incur additional losses until significant revenue generation occurs, which is not anticipated in the near future [60]. Expenses - Research and development expenses for the six months ended June 30, 2024, were $1.4 million, up from $1.1 million in the same period of 2023, indicating a 27% increase [50]. - General and administrative expenses rose significantly to $1.6 million for the six months ended June 30, 2024, compared to $0.1 million in the same period of 2023, reflecting a 1500% increase [51]. - Interest expenses surged to $4.3 million for the six months ended June 30, 2024, from $0.1 million in the same period of 2023, marking a 4200% increase [52]. - The company expects research and development expenses to remain consistent with 2024 levels as it advances TELOMIR-1 through clinical trials [50]. Cash Position and Financing - The company had cash and cash equivalents of approximately $1.9 million as of June 30, 2024, with an accumulated deficit of approximately $21.7 million [60]. - Financing activities provided $5.3 million of cash for the six months ended June 30, 2024, primarily from $5.8 million in proceeds from the sale of common stock [64]. - The company plans to conduct a capital raise in the near future to assist in financing working capital needs [56]. - The total amount advanced by MIRALOGX to the company was $1.7 million, which was converted into 837,841 shares of common stock at a conversion rate of $2.05 per share [59].

Core Points - Telomir Pharmaceuticals has appointed Erez Aminov as the new CEO and Chairman of the Board following the passing of the previous Chairman and CEO, Dr. Christopher Chapman, Jr. [1][2] - The company is focused on developing Telomir-1, a novel small molecule aimed at promoting longevity by lengthening telomeres, which are protective caps on chromosomes [5]. Management Changes - Erez Aminov, previously the CEO of MIRA Pharmaceuticals, has taken over leadership roles at Telomir [2]. - Three directors have resigned from the Board to support the new management, with three new directors appointed: Dr. Matthew P. Del Giudice, Mr. Ned MacPherson, and Matthew Pratt Whalen, CPA [3]. - Current directors Dr. Craig Eagle and Michael Jerman will remain on the Board [3]. Company Overview - Telomir Pharmaceuticals is in the pre-clinical stage, focusing on Telomir-1 to address age-related conditions in both humans and dogs [5]. - The company aims to enhance quality of life by potentially preventing degenerative diseases associated with aging through its drug candidate [5].

Core Insights - Telomir Pharmaceuticals, Inc. has been added to the Russell 3000® and Russell Microcap® Indexes, effective July 1, 2024, indicating significant progress as a publicly-traded company since its IPO in February 2024 [1][6][11] Company Overview - Telomir Pharmaceuticals is a pre-clinical-stage pharmaceutical company focused on developing and commercializing Telomir-1, a novel small molecule aimed at lengthening DNA's protective telomere caps to potentially treat age-related conditions [1][13] - The company aims to address a range of age-related inflammatory conditions, including osteoarthritis, through the oral administration of Telomir-1 [13] Industry Context - The Russell indexes are widely utilized by investment managers and institutional investors, with approximately $10.5 trillion in assets benchmarked against these indexes as of December 2023 [2][11] - Membership in the Russell 3000® and Russell Microcap® Indexes provides automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, enhancing visibility and credibility in the market [11]

Company Overview - Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on developing and commercializing Telomir-1, a novel small molecule aimed at lengthening DNA's protective telomere caps to potentially reverse age-related conditions [12]. Recent Developments - Telomir has been added to the Russell 3000® and Russell Microcap® Indexes, effective July 1, 2024, as part of the 2024 Russell indexes reconstitution, indicating progress as a publicly-traded company since its IPO in February [9][8]. - The company aims to achieve corporate and clinical objectives in the second half of 2024 and beyond, particularly for its lead product candidate, Telomir-1 [8]. Market Context - The Russell indexes are widely utilized by investment managers and institutional investors for index funds and as benchmarks for active investment strategies, with approximately $10.5 trillion in assets benchmarked against these indexes as of December 2023 [10].